Clinical trial · Interventional
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
Phase 2 Study of Weekly Topotecan With Docetaxel for Recurrent Small Cell Lung Cancer
NCT00315211CI-TRIAL-00034439terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow Accrual
Summary
Brief summary (as posted)
The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mediastinal Neoplasms | Mediastinal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Arm A
- description
- Weekly intravenous topotecan with intravenous docetaxel
- interventionNames
- Drug: Intravenous Topotecan
- Drug: Intravenous Docetaxel
Primary outcomes (1)
- measure
- To determine the overall response rate of patients treated with at least two cycles of topotecan and docetaxel
- timeFrame
- 3 years
- description
- To determine the overall response rate of patients treated with at least two cycles of topotecan and docetaxel
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Recurred greater than 90 days after initial treatment * At least 1 measurable lesion * Only 1 prior chemotherapy * Must be over 18 years of age * ECOG performance status of 0 - 2 * Adequate hematologic, renal, and hepatic function Exclusion Criteria: * No prior use of topotecan, docetaxel, or irinotecan * No symptomatic brain metastases * History of cardiac arrhythmias, congestive heart failure, stroke, or embolic events * No prior investigational agents within 1 month prior * Lung cancer of mixed histology * Known uncontrolled seizure disorders
References
Publications (0)
Data not yet available
No reference posted for this study.